Wed, Jan 28, 2015, 4:29 AM EST - U.S. Markets open in 5 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • efficient_frontier2002 efficient_frontier2002 Jan 19, 2010 11:36 AM Flag

    Broad interest in SNTA's STA-9090 inhibitor

    From the last conference call ...

    http://seekingalpha.com/article/171292-synta-pharmaceuticals-corp-q3-2009-earnings-call-transcript?page=1

    "We have been helped over the past several months in our progress towards this goal [of advancing 9090] by the broad support we have received from investigators around the country and their interest in expansion trials with this compound.

    Many of these investigators have worked with other Hsp90 inhibitors and their support for 9090 is encouraging for us and for the program. The majority of the new trials will be investigator sponsored. Meaning that they will cost as much less than a typical company sponsored trial."


    My comments: Most biotech companies are pretty excited about their products. But I think it's unusual, and very encouraging, when so many people outside of the company are just as excited, and are willing to foot a large part of the research bill.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • nice info... Thanks for your investigation!!

      • 1 Reply to funinmy50s
      • efficient_frontier2002 efficient_frontier2002 Jan 20, 2010 11:28 AM Flag

        You're welcome.

        Here are two more encouraging excerpts from the same conference call ...


        1. "Based on the pace of discussions and level of interest I can say we are optimistic we will be able to generate one or more partnerships in the first half of [2010]. We are fortunate to have multiple un-partnered programs, a strong discovery engine and a good cash position, all of which gives us flexibility and we intent to use that flexibility as an advantage to get the best choices on the table."


        2. "Brian Martin - Barclays Capital

        But 9090 clearly you all have shown pre-clinical data that's shown to be superior during the first generation 17 AAG and analogues. But how do you see yourselves positioned versus other earlier stage synthetic compounds like in Pfizer Serenex 5422 or the Astex compound or the Novartis compounds.

        Vojo Vukovic (SNTA)

        I think that's a great question. Let me begin by answering the question that we have synthesized in our labs really all of the claimed Hsp90 inhibitors that we are aware of for which the structures under public premise, we're able to do extensive testing in our labs and by our experiments as well as the experienced results from our collaborators we see that 9090 is FAR SUPERIOR (my caps) to 17-AG family of inhibitors that a number of companies are developing."

 
SNTA
2.53+0.03(+1.20%)Jan 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Microsoft Corporation
NASDAQTue, Jan 27, 2015 4:00 PM EST
Caterpillar Inc.
NYSETue, Jan 27, 2015 4:00 PM EST